A new anthracycline regimen for prolymphocytic leukemia? Study of a case report with flow cytometric implications
A case of prolymphocytic leukemia (PL) is reported, which showed a good response to a new antiblastic schedule (4-epidoxorubicin-asparaginase-dexamethasone) in spite of the resistance to other chemotherapy regimens. However during the course of the disease it was possible to observe the terminal app...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 1987, Vol.11 (10), p.947-949 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 949 |
|---|---|
| container_issue | 10 |
| container_start_page | 947 |
| container_title | Leukemia research |
| container_volume | 11 |
| creator | Franchi, Fabrizio Seminara, Patrizia Codacci-Pisanelli, Giovanni Familiari, Maria Teodori, Laura Göhde, Wolfgang |
| description | A case of prolymphocytic leukemia (PL) is reported, which showed a good response to a new antiblastic schedule (4-epidoxorubicin-asparaginase-dexamethasone) in spite of the resistance to other chemotherapy regimens. However during the course of the disease it was possible to observe the terminal appearance of a small aneuploid cell population in the peripheral blood of the patient and, in the same time, the clinical condition deteriorated considerably. The significance of this neoplastic progression and the pros and cons of aggressive chemotherapy regimens remain to be carefully evaluated in PL and related disorders. |
| doi_str_mv | 10.1016/0145-2126(87)90141-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77836936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>014521268790141X</els_id><sourcerecordid>77836936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-b56a402ddef2ddffd324cf96e9ad856154187c73b905a339d1b4e35f3c2d302a3</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo67j6DxRyENFDa9LppDuXlWXxCxY8qLC3kEkqTjTd6U3SDv3vzTjDHL1UKOp5i9SD0HNK3lJCxTtCO960tBWvh_6NrB1t7h6gDR161vCB8Ydoc0Yeoyc5_yKEcEnlBbpgXS-F4Bt0f40n2GM9lV3SZjXBT4AT_PQjTNjFhOcUwzrOu2jW4g0OsPyG0ev3-FtZ7IqjwxobnQ-hOaaC977ssAtxj2sgjlBSTflxDt7o4uOUn6JHTocMz07vJfrx8cP3m8_N7ddPX26ubxvDBlGaLRe6I6214GpxzrK2M04KkNoOXFDe1UNNz7aScM2YtHTbAeOOmdYy0mp2iV4d99YL7hfIRY0-GwhBTxCXrPp-YEIyUcHuCJoUc07g1Jz8qNOqKFEH0-qgUR00qqFX_0yruxp7cdq_bEew59BJbZ2_PM11Njq4pCfj8xnrBZNDyyp2dcSguvjjIalsPEwGrE9girLR__8ffwGTgpxu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77836936</pqid></control><display><type>article</type><title>A new anthracycline regimen for prolymphocytic leukemia? Study of a case report with flow cytometric implications</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Franchi, Fabrizio ; Seminara, Patrizia ; Codacci-Pisanelli, Giovanni ; Familiari, Maria ; Teodori, Laura ; Göhde, Wolfgang</creator><creatorcontrib>Franchi, Fabrizio ; Seminara, Patrizia ; Codacci-Pisanelli, Giovanni ; Familiari, Maria ; Teodori, Laura ; Göhde, Wolfgang</creatorcontrib><description>A case of prolymphocytic leukemia (PL) is reported, which showed a good response to a new antiblastic schedule (4-epidoxorubicin-asparaginase-dexamethasone) in spite of the resistance to other chemotherapy regimens. However during the course of the disease it was possible to observe the terminal appearance of a small aneuploid cell population in the peripheral blood of the patient and, in the same time, the clinical condition deteriorated considerably. The significance of this neoplastic progression and the pros and cons of aggressive chemotherapy regimens remain to be carefully evaluated in PL and related disorders.</description><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/0145-2126(87)90141-X</identifier><identifier>PMID: 3479665</identifier><identifier>CODEN: LEREDD</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>4-epidoxorubicin ; anthracyclines ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asparaginase - administration & dosage ; Biological and medical sciences ; chemoresistance ; Chemotherapy ; Dexamethasone - administration & dosage ; Doxorubicin - administration & dosage ; Drug Administration Schedule ; Epirubicin ; Flow Cytometry ; Humans ; Leukemia, Lymphoid - drug therapy ; Male ; Medical sciences ; Middle Aged ; neoplastic progression ; Pharmacology. Drug treatments ; Prolymphocytic leukemia ; tumor cell heterogeneity</subject><ispartof>Leukemia research, 1987, Vol.11 (10), p.947-949</ispartof><rights>1987</rights><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-b56a402ddef2ddffd324cf96e9ad856154187c73b905a339d1b4e35f3c2d302a3</citedby><cites>FETCH-LOGICAL-c386t-b56a402ddef2ddffd324cf96e9ad856154187c73b905a339d1b4e35f3c2d302a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0145-2126(87)90141-X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7639823$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3479665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Franchi, Fabrizio</creatorcontrib><creatorcontrib>Seminara, Patrizia</creatorcontrib><creatorcontrib>Codacci-Pisanelli, Giovanni</creatorcontrib><creatorcontrib>Familiari, Maria</creatorcontrib><creatorcontrib>Teodori, Laura</creatorcontrib><creatorcontrib>Göhde, Wolfgang</creatorcontrib><title>A new anthracycline regimen for prolymphocytic leukemia? Study of a case report with flow cytometric implications</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>A case of prolymphocytic leukemia (PL) is reported, which showed a good response to a new antiblastic schedule (4-epidoxorubicin-asparaginase-dexamethasone) in spite of the resistance to other chemotherapy regimens. However during the course of the disease it was possible to observe the terminal appearance of a small aneuploid cell population in the peripheral blood of the patient and, in the same time, the clinical condition deteriorated considerably. The significance of this neoplastic progression and the pros and cons of aggressive chemotherapy regimens remain to be carefully evaluated in PL and related disorders.</description><subject>4-epidoxorubicin</subject><subject>anthracyclines</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asparaginase - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>chemoresistance</subject><subject>Chemotherapy</subject><subject>Dexamethasone - administration & dosage</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>Epirubicin</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Leukemia, Lymphoid - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>neoplastic progression</subject><subject>Pharmacology. Drug treatments</subject><subject>Prolymphocytic leukemia</subject><subject>tumor cell heterogeneity</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE2LFDEQhoMo67j6DxRyENFDa9LppDuXlWXxCxY8qLC3kEkqTjTd6U3SDv3vzTjDHL1UKOp5i9SD0HNK3lJCxTtCO960tBWvh_6NrB1t7h6gDR161vCB8Ydoc0Yeoyc5_yKEcEnlBbpgXS-F4Bt0f40n2GM9lV3SZjXBT4AT_PQjTNjFhOcUwzrOu2jW4g0OsPyG0ev3-FtZ7IqjwxobnQ-hOaaC977ssAtxj2sgjlBSTflxDt7o4uOUn6JHTocMz07vJfrx8cP3m8_N7ddPX26ubxvDBlGaLRe6I6214GpxzrK2M04KkNoOXFDe1UNNz7aScM2YtHTbAeOOmdYy0mp2iV4d99YL7hfIRY0-GwhBTxCXrPp-YEIyUcHuCJoUc07g1Jz8qNOqKFEH0-qgUR00qqFX_0yruxp7cdq_bEew59BJbZ2_PM11Njq4pCfj8xnrBZNDyyp2dcSguvjjIalsPEwGrE9girLR__8ffwGTgpxu</recordid><startdate>1987</startdate><enddate>1987</enddate><creator>Franchi, Fabrizio</creator><creator>Seminara, Patrizia</creator><creator>Codacci-Pisanelli, Giovanni</creator><creator>Familiari, Maria</creator><creator>Teodori, Laura</creator><creator>Göhde, Wolfgang</creator><general>Elsevier Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1987</creationdate><title>A new anthracycline regimen for prolymphocytic leukemia? Study of a case report with flow cytometric implications</title><author>Franchi, Fabrizio ; Seminara, Patrizia ; Codacci-Pisanelli, Giovanni ; Familiari, Maria ; Teodori, Laura ; Göhde, Wolfgang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-b56a402ddef2ddffd324cf96e9ad856154187c73b905a339d1b4e35f3c2d302a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>4-epidoxorubicin</topic><topic>anthracyclines</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asparaginase - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>chemoresistance</topic><topic>Chemotherapy</topic><topic>Dexamethasone - administration & dosage</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>Epirubicin</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Leukemia, Lymphoid - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>neoplastic progression</topic><topic>Pharmacology. Drug treatments</topic><topic>Prolymphocytic leukemia</topic><topic>tumor cell heterogeneity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Franchi, Fabrizio</creatorcontrib><creatorcontrib>Seminara, Patrizia</creatorcontrib><creatorcontrib>Codacci-Pisanelli, Giovanni</creatorcontrib><creatorcontrib>Familiari, Maria</creatorcontrib><creatorcontrib>Teodori, Laura</creatorcontrib><creatorcontrib>Göhde, Wolfgang</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Franchi, Fabrizio</au><au>Seminara, Patrizia</au><au>Codacci-Pisanelli, Giovanni</au><au>Familiari, Maria</au><au>Teodori, Laura</au><au>Göhde, Wolfgang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A new anthracycline regimen for prolymphocytic leukemia? Study of a case report with flow cytometric implications</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>1987</date><risdate>1987</risdate><volume>11</volume><issue>10</issue><spage>947</spage><epage>949</epage><pages>947-949</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><coden>LEREDD</coden><abstract>A case of prolymphocytic leukemia (PL) is reported, which showed a good response to a new antiblastic schedule (4-epidoxorubicin-asparaginase-dexamethasone) in spite of the resistance to other chemotherapy regimens. However during the course of the disease it was possible to observe the terminal appearance of a small aneuploid cell population in the peripheral blood of the patient and, in the same time, the clinical condition deteriorated considerably. The significance of this neoplastic progression and the pros and cons of aggressive chemotherapy regimens remain to be carefully evaluated in PL and related disorders.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>3479665</pmid><doi>10.1016/0145-2126(87)90141-X</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 1987, Vol.11 (10), p.947-949 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77836936 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | 4-epidoxorubicin anthracyclines Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asparaginase - administration & dosage Biological and medical sciences chemoresistance Chemotherapy Dexamethasone - administration & dosage Doxorubicin - administration & dosage Drug Administration Schedule Epirubicin Flow Cytometry Humans Leukemia, Lymphoid - drug therapy Male Medical sciences Middle Aged neoplastic progression Pharmacology. Drug treatments Prolymphocytic leukemia tumor cell heterogeneity |
| title | A new anthracycline regimen for prolymphocytic leukemia? Study of a case report with flow cytometric implications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T23%3A34%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20new%20anthracycline%20regimen%20for%20prolymphocytic%20leukemia?%20Study%20of%20a%20case%20report%20with%20flow%20cytometric%20implications&rft.jtitle=Leukemia%20research&rft.au=Franchi,%20Fabrizio&rft.date=1987&rft.volume=11&rft.issue=10&rft.spage=947&rft.epage=949&rft.pages=947-949&rft.issn=0145-2126&rft.eissn=1873-5835&rft.coden=LEREDD&rft_id=info:doi/10.1016/0145-2126(87)90141-X&rft_dat=%3Cproquest_cross%3E77836936%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77836936&rft_id=info:pmid/3479665&rft_els_id=014521268790141X&rfr_iscdi=true |